Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349468 | 1.00 | NPC1 (0.52) | NPC1NAAACA1CA2HPGD | |
| SCHEMBL6379649 | 1.00 | NPC1 (0.52) | NPC1NAAACA1CA2HPGD | |
| SCHEMBL3762069 | 0.97 | — | — | |
| SCHEMBL130811 | 0.92 | — | — | |
| SCHEMBL9341295 | 0.86 | NPC1 (0.45) | NPC1HPGD | |
| SCHEMBL127441 | 0.86 | — | — | |
| SCHEMBL6381063 | 0.85 | NPC1 (0.48) | NPC1NAAA | |
| SCHEMBL1259504 | 0.85 | NPC1 (0.48) | NPC1NAAA | |
| SCHEMBL6385423 | 0.85 | NPC1 (0.48) | NPC1NAAA | |
| SCHEMBL9339598 | 0.84 | NPC1 (0.44) | NPC1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | KING ABDULAZIZ UNIVERSITY (SA) | 2021-03-30 | — | — | US | claimed |
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | KING ABDULAZIZ UNIVERSITY (SA) | 2020-10-15 | — | — | US | claimed |
| US-20050076578-A1 | Tunable composition and method for chemical-mechanical planarization with aspartic acid/tolyltriazole | VERSUM MATERIALS US, LLC | 2005-04-14 | — | — | US | claimed |
| US-6114534-A | REACTING A KETONE DERIVATIVE OF CARBAMOYL SUBSTITUTED HETEROCYCLE WITH PHOSPHORANE, FOLLOWED BY ACIDIFICATION TO FORM AN ANTICOAGULANT | ELI LILLY AND COMPANY (US) | 2000-09-05 | — | — | US | claimed |
| US-6075147-A | OMEGA-PHENYL-OMEGA-(3-PYRIDYL)-OMEGA-ALKENOIC ACID DERIVATIVES BEARING A CARBAMOYL SUBSTITUTED OXAZOLYL OR OXAZOLINYL GROUP ON THE PHENYL RING IS USEFUL FOR THROMBOXANE RECEPTOR ANTAGONSIM OR THROMBOXANE SYNTHASE INHIBITOR | ELI LILLY AND COMPANY (US) | 2000-06-13 | — | — | US | claimed |
| US-6031095-A | Intermediates in the preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | claimed |
| US-5990308-A | Intermediates in the preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1999-11-23 | — | — | US | claimed |
| US-5849922-A | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | claimed |
| US-5849766-A | Carbamoyl substituted heterocycles | ELI LILLY AND COMPANY (US) | 1998-12-15 | — | — | US | claimed |
| EP-0816361-A2 | Preparation of substituted alkenoic acids | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| EP-0811621-A2 | Carbamoyl substituted oxazoles as thromboxane receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | claimed |
| EP-0596197-B1 | Lubricating composition comprising an N-acyl-N-hydrocarbon- oxyalkyl aspartic acid compound | KING INDUSTRIES INC (US) | 1997-01-29 | — | — | EP | claimed |
| EP-0596197-A1 | Lubricating composition comprising an N-acyl-N-hydrocarbon- oxyalkyl aspartic acid compound | KING INDUSTRIES, INC. (US) | 1994-05-11 | — | — | EP | claimed |
| US-5275749-A | Lubricants with corrosion inhibitors | KING INDUSTRIES, INC. (US) | 1994-01-04 | — | — | US | claimed |
| CN-111302926-B | Beta-diketone cerium (IV) compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024064178-A1 | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2023233895-A1 | POLYIMIDE RESIN PRECURSOR | 東京応化工業株式会社 | 2023-12-07 | — | — | WO | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
| US-4144166-A | Compositions, apparatus and methods useful for releasing solid lubricating oil additive | ATLANTIC RICHFIELD COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4094799-A | CONTAINING A COPOLYMER OF A VINYLPYRROLIDONE AND AN ACRYLIC ESTER | ATLANTIC RICHFIELD COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323822-A1 | IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, ZC3HAV1 | NPC1 147/4885NAAA 1086/4885CA1 4694/4885 |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | HAVCR2, MAVS, ZC3HAV1 | NPC1 147/4885NAAA 1086/4885CA1 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.